For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Vesugen (Lys-Glu-Asp, KED) is a synthetic tripeptide derived from vascular wall protein sequences, developed by Professor Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the most clinically studied Khavinson bioregulator to cross into human territory: small Russian observational studies in atherosclerosis patients, post-surgical lower limb ischemia cases, and vasculogenic erectile dysfunction report meaningful improvements in vascular endpoints. The mechanistic work, including Ki-67 gene promoter docking, SIRT1 upregulation, and endothelin-1 normalization in endothelial cultures, is more developed than most Khavinson compounds. None of the human studies were randomized, blinded, or placebo-controlled, and all originate from a single research institution.
Vesugen is a research compound with no FDA or EMA approval and no completed randomized controlled human clinical trials for any indication. The human data cited in vendor materials and some review papers come from small, uncontrolled Russian observational studies, specifically in elderly patients with atherosclerosis, post-surgical lower limb ischemia, and vasculogenic erectile dysfunction. These are not clinical trials by Western regulatory standards. They provide directional signals, not validated evidence of efficacy.
Vendor content routinely describes Vesugen as having "extensive clinical validation." This is inaccurate. The human studies identified are unblinded, uncontrolled observational series from a single institutional source. No independent replication in a Western clinical trial setting has been published. The distinction between peer-reviewed observational data and controlled trial evidence matters enormously for this class of compound.
The entire Vesugen research base originates from one group: Professor Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology, with essentially the same core authors across all primary publications. This is the same structural limitation shared by Epithalon, Cortagen, and Vilon. The 2021 5xFAD Alzheimer's mouse study (Khavinson et al., Pharmaceuticals) is an exception in that it was conducted with international co-authors and published in an MDPI open-access journal, providing some external institutional involvement, but Khavinson remains the senior author.
The claim that oral Vesugen "improved memory and attention in elderly individuals with functional CNS disorders" appears in a 2021 review paper (Khavinson, Linkova, Umnov, Bulletin of Experimental Biology and Medicine) as a background statement citing earlier unpublished or Russian-language clinical reports. No primary publication of that finding has been independently identified and characterized. It should not be treated as established clinical evidence.
Vesugen (also designated T-38 or KED peptide) is a synthetic tripeptide with the sequence Lys-Glu-Asp, derived by directed amino acid analysis of vascular wall protein preparations. It was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the late 1990s and formally patented in 2006 (Russian patent by OOO SIA Peptaids, inventors: Khavinson, Grigor'ev, Malinin, Ryzhak).
The design logic followed the same principle used to produce the other Khavinson bioregulators: identify the most abundant amino acids in biologically active tissue extracts and synthesize their minimal sequence as a candidate active fraction. For Vesugen, the tissue of origin was vascular wall, selecting it as a candidate endothelial bioregulator. Unlike the thymic bioregulators (Vilon, Thymogen) or pineal bioregulators (Epithalon), Vesugen targets the cardiovascular endothelium, the inner cellular lining of blood vessels that governs vascular tone, inflammation, permeability, and repair.
The vascular endothelium is a critical interface between blood and vessel wall. Endothelial dysfunction, characterized by impaired nitric oxide production, elevated inflammatory signaling, and reduced regenerative capacity, is a common early driver of atherosclerosis, hypertension, and organ ischemia. Age-related loss of endothelial proliferative capacity, measured by declining Ki-67 protein expression, is well characterized. Vesugen's proposed utility is restoring gene expression in aging endothelial cells to slow this decline.
Vesugen shares the Lys-Glu-Asp (KED) core with several other Khavinson bioregulators. Livagen (Lys-Glu-Asp-Ala) extends the KED tripeptide by one alanine residue and targets lymphocyte chromatin remodeling. Testagen (Lys-Glu-Asp-Gly) adds a glycine and targets testicular tissue. The shared KED motif is increasingly discussed as a fundamental bioregulatory sequence, with C-terminal additions determining tissue specificity. Whether these sequence relationships produce genuinely organ-specific effects in vivo or primarily reflect the theoretical framework of the bioregulator design program remains an open question.
Vesugen's proposed primary mechanism is epigenetic regulation of vascular endothelial gene expression through direct peptide-DNA interaction. The 2014 Khavinson/Tarnovskaya paper (Advances in Gerontology, also available in translation) used molecular docking to model Vesugen binding to the promoter region of the MKI67 gene, which encodes Ki-67, a protein that marks actively dividing cells. Vesugen was shown to interact with a CATC sequence in the core promoter region, forming hydrogen bonds in the DNA minor groove. In parallel cell culture experiments, Vesugen stimulated Ki-67 protein expression in vascular endothelial cell cultures from aged animals, which showed reduced Ki-67 expression compared to young controls.
Ki-67 is a proliferation marker but also a structural component of chromosomes with proposed roles in chromatin organization. Its decline in aging endothelium correlates with reduced regenerative capacity: fewer new endothelial cells to replace those lost to apoptosis, shear stress, or oxidative damage. The hypothesis is that Vesugen restores a more youthful proliferative state in aging endothelium by upregulating MKI67 gene transcription, thereby maintaining vascular wall integrity.
A second mechanism involves normalization of endothelin-1 expression. Endothelin-1 is a potent vasoconstrictor and pro-inflammatory signaling molecule that is upregulated in atherosclerosis and restenosis. The 2016 Kozlov/Linkova/Khavinson paper (Advances in Gerontology) reported that in human endothelial cell cultures under conditions modeling atherosclerosis, Vesugen normalized endothelin-1 expression toward control levels. Endothelin-1 overexpression is a well-validated driver of vascular dysfunction; its normalization by a small peptide would constitute meaningful pharmacology if replicated in vivo.
A third mechanism is SIRT1 upregulation. SIRT1 (Sirtuin-1) is a NAD-dependent deacetylase that modulates endothelial function, promotes nitric oxide production, inhibits NF-kB-mediated vascular inflammation, and is considered a key mediator of the vascular benefits of calorie restriction. Several secondary sources cite Vesugen-induced SIRT1 upregulation in endothelial cells, though the primary peer-reviewed source for this specific claim is not uniformly cited with full study details.
A fourth mechanism involves connexin gap junction restoration. Connexins are proteins forming intercellular channels that coordinate endothelial cell behavior, including blood pressure responses and paracrine signaling. The Kozlov 2016 paper and companion studies report that Vesugen restores connexin expression that is reduced in atherosclerotic endothelium. This restoration of cell-to-cell communication is proposed to improve coordinated endothelial function.
In neural models, Vesugen (KED) has been tested separately. The 2021 Pharmaceuticals study (Khavinson, Ilina et al.) administered KED at 400 mcg/kg intraperitoneally to 5xFAD Alzheimer's transgenic mice and found a positive trend toward increased neuroplasticity, though the paper's primary findings focused on a related EDR peptide. A 2017 cell culture study (Kraskovskaya et al., Bulletin of Experimental Biology and Medicine) demonstrated that KED, alongside other tripeptides, restored neuronal spine density in an in vitro amyloid synaptotoxicity model. The molecular docking analysis identifies binding sites for KED in promoters of genes including NES (nestin), GAP43, p16, and p21, consistent with Vesugen influencing neuronal differentiation and senescence programs through the same chromatin-binding mechanism proposed for vascular tissue.
The 2014 Khavinson/Tarnovskaya docking and cell culture study demonstrated that Vesugen stimulated Ki-67 protein expression in vascular endothelial cell cultures from aged animals, in which Ki-67 had declined relative to young-animal cultures. Molecular docking identified a binding interaction between Vesugen and the CATC motif in the MKI67 core promoter, with hydrogen bond formation in the DNA minor groove. This is one of the more mechanistically specific findings in the Khavinson bioregulator literature.
The 2016 Kozlov et al. paper reported that Vesugen normalized elevated endothelin-1 expression in human endothelial cell cultures modeling atherosclerosis, restored connexin expression (a marker of intercellular gap junction communication), and increased SIRT1 expression. These are three distinct and clinically relevant molecular targets in vascular endothelial dysfunction.
The 2014 Malinin et al. Bulletin paper reported that Lys-Glu-Asp specifically improved connexin-mediated cell-to-cell communication and endothelial proliferation under both normal and atherosclerotic conditions in culture.
The 2013 Kitachov clinical study of 41 post-surgical lower limb ischemia patients treated with Vesugen as monotherapy found significant improvements in lower limb blood flow by ultrasonic measurement, with favorable clinical outcomes. This is the largest and most clinically direct human dataset. However, there was no control arm, no blinding, and all patients had undergone recent surgical intervention, making it impossible to separate Vesugen's contribution from post-surgical recovery.
The mechanistic work on Ki-67 promoter binding, endothelin-1 normalization, and SIRT1 upregulation in endothelial cultures is the strongest molecular story in the Vesugen literature and is more developed than most Khavinson compounds. The n=41 clinical study in lower limb ischemia provides human directional signal. But the cell culture data are in vitro, the clinical data are uncontrolled, and all findings come from one research group. This is a plausible and mechanistically coherent body of work that requires independent controlled trials before clinical conclusions can be drawn.
A translated passage from Khavinson's Advances in Gerontology paper (accessed via the khavinson.info archive) states that oral Vesugen, combined with conventional atherosclerosis therapy, was more effective than standard therapy alone in elderly patients, producing decreased angina frequency, reduced cardiac arrhythmia manifestations, and normalized sleep patterns.
In elderly essential hypertension patients, oral Vesugen combined with antihypertensive therapy produced what the authors described as long-term remission between hypertensive crises and decreased total cholesterol and VLDL levels in blood.
These are clinically meaningful endpoints if accurate. The critical limitations are substantial: no patient count is given; no control arm is described; blinding status is unclear; the primary source is a Russian-language review paper citing earlier work rather than an original clinical trial publication. Independent verification of these findings is not possible from available indexed literature.
These observations, if real, would represent meaningful clinical activity in two high-prevalence cardiovascular conditions. They also represent the kind of claims that require prospective controlled trials before they can inform clinical practice. The absence of patient counts, control arms, and accessible primary publications makes it impossible to assess the quality of the underlying data. These are clinical signals worth pursuing in properly designed trials, not established efficacy claims.
A 2014 observational study investigated Vesugen in elderly patients with vasculogenic erectile dysfunction secondary to lower limb atherosclerosis. Clinical assessments and instrumental blood flow measurements in the main penile arteries were conducted before and after treatment. The results demonstrated significant improvements in penile arterial blood flow, with both clinical outcomes and objective Doppler parameters improving following Vesugen administration.
The study concluded that Vesugen is an effective peptide bioregulator for improving vascular function in patients with atherosclerosis-related erectile dysfunction. The design is uncontrolled and likely unblinded. The patient population (atherosclerosis-related vasculogenic ED) is clinically well defined and appropriate for testing a vascular bioregulator. The reported outcome (improved penile arterial blood flow) is mechanistically coherent with the endothelial function mechanism.
No further details on sample size, follow-up duration, or effect magnitude are available from the indexed abstract or secondary sources.
Vasculogenic erectile dysfunction is a legitimate and underserved clinical target, and an endothelial bioregulator with the mechanism Vesugen proposes could plausibly improve penile arterial blood flow. The finding is mechanistically coherent and the clinical population is appropriate. The evidence is an uncontrolled pre-post observational study with no comparator. It does not establish efficacy but provides a directional clinical signal in a defined population.
The 2021 5xFAD mouse study found that intraperitoneal KED at 400 mcg/kg daily from age 2 to 4 months produced a positive trend toward increased neuroplasticity in this aggressive Alzheimer's transgenic model. KED and the companion EDR peptide both prevented dendritic spine loss in 5xFAD mice exposed to amyloid synaptotoxicity conditions. The primary mechanistic finding was molecular docking identifying KED binding sites in promoters of neuronal differentiation genes including NES and GAP43, and Alzheimer's disease-related genes including SUMO, APOE, and IGF1.
The 2017 Kraskovskaya cell culture study demonstrated that KED restored neuronal spine number under in vitro amyloid synaptotoxicity conditions, alongside EDR and AEDG. The effect was observed at peptide concentrations consistent with other Khavinson bioregulator studies.
The 2021 BEMBM review paper by Khavinson, Linkova, and Umnov states that oral application of KED improved memory and attention in elderly individuals with functional CNS disorders. This claim cites a 2008 Russian-language paper (Balashova, Zhernakov, Dudkov, Uspekhi Gerontologii) describing application of bioregulators in elderly with psychoemotional disorders. The specificity of Vesugen's contribution, the study design quality, and the definition of "functional CNS disorders" in this context are not verifiable from available indexed sources.
The 2024 PMC study (Khavinson et al., published in Frontiers or equivalent) showed that KED promoted dendritic arborization in fibroblast-derived induced neurons from elderly donors, increasing both primary process number and total dendrite length, alongside EDR and AEDG.
The neuroprotection findings in Alzheimer's models are mechanistically consistent with the broader Khavinson bioregulator paradigm and involve internationally co-authored work published in PubMed-indexed journals. The dendritic spine preservation and gene expression findings are genuine cell biology results. The mouse model is 5xFAD, an aggressive multi-mutation model that does not represent typical Alzheimer's pathology. The human claim regarding memory improvement in elderly individuals is from a Russian observational report that cannot be independently assessed. No prospective neuroprotection trial exists.
Vesugen is cited in multiple Khavinson review papers as demonstrating geroprotective properties through SIRT1 pathway activation, which the group positions as a calorie restriction mimetic mechanism. SIRT1 deacetylase activity is associated with vascular health, reduced inflammatory gene transcription, and improved insulin sensitivity in endothelial cells. The proposed connection between Vesugen's endothelial SIRT1 upregulation and systemic geroprotection is mechanistically extrapolated rather than measured in aging outcome studies.
The 2008 Kozina antihypoxia study found that short peptides in the Khavinson bioregulator family, including KED-related sequences, improved hypoxia resistance in rodent models, suggesting enhanced mitochondrial or metabolic resilience under oxygen deprivation.
Improved biological age markers in elderly patients are cited in Khavinson review literature as observed outcomes of Vesugen protocols, but the specific study designs, patient numbers, and measurement instruments underlying these claims are not consistently identified in accessible indexed sources. These claims are institutional narrative rather than primary trial data.
The SIRT1 mechanism connecting Vesugen to geroprotection is biologically plausible and consistent with established vascular aging biology. The antihypoxia rodent data are real but limited in scope. The biological age improvement claims in humans cannot be independently evaluated from available indexed literature. Vesugen's geroprotective case rests primarily on inference from its vascular mechanism rather than longevity endpoint data.
Khavinson bioregulator peptide.
No human pharmacokinetic study has been published for Vesugen. Russian observational clinical data describe both oral and injectable use with reported clinical benefits in cardiovascular patients, but without systematic dose characterization. The dose range shown (200 to 2000 mcg) reflects the spread of commercial protocols, not validated dose-finding. Animal neuroprotection studies used 400 mcg/kg IP in mice, which translates to approximately 32 mcg/kg in humans by standard allometric scaling, or roughly 2000 to 2500 mcg for a 70 kg adult, coincidentally aligning with the high commercial protocol dose but without clinical validation.
Within the Khavinson bioregulator family, Vesugen has the most developed human exposure record for cardiovascular indications. Epithalon has attracted more Western interest due to the telomere-lengthening hypothesis, but has no comparable clinical observational data in a defined disease population. Vilon has the most extensive animal longevity data but carries the HER-2/neu safety signal. Livagen shares the KED core sequence but is studied primarily for lymphocyte chromatin remodeling. Outside the Khavinson family, the vascular endothelial function space is occupied by compounds with much stronger evidence bases: statins, ACE inhibitors, and GLP-1 agonists all have Phase 3 RCT data and regulatory approval for cardiovascular indications that Vesugen has not attempted to match. Vesugen's closest competitor concept, as a peptide-based endothelial bioregulator, would be ongoing research into eNOS-activating peptides or SIRT1 activators in Phase 2 development, none of which have direct head-to-head comparison data with KED.
No formal pharmacokinetic or safety studies in humans have been published for Vesugen. No phase 1 dose-escalation trial has been conducted. The human observational studies in Russia report good tolerability, but without systematic adverse event collection, blinding, or control arms, this is not equivalent to a safety profile.
In the animal models and cell culture studies, no toxicity signals have been reported. The compound is composed entirely of amino acids present in normal human physiology. Tripeptides of this size are rapidly metabolized by peptidases in blood and tissue. Unlike larger peptides, they are unlikely to generate antibody responses.
The 2013 and 2017 lower limb ischemia studies (Kitachov/Kozlov group, Advances in Gerontology) reported no serious adverse events among n=41 post-surgical patients treated with Vesugen. The 2014 erectile dysfunction study reported no adverse effects. The Russian clinical narrative on Vesugen consistently describes it as well tolerated, but these reports come from an advocacy context rather than systematic safety assessment.
No drug interactions have been published. No organ toxicity data exist. No chronic administration safety data in humans exist. Mild injection-site reactions are expected with any subcutaneous peptide, as with all compounds in this series.
The most significant known unknown is the oral bioavailability question. Vesugen is widely sold in oral formulations and the Russian observational data describe oral use producing clinical effects. Whether KED survives gastric acid and intestinal peptidases to reach systemic circulation is not established by published pharmacokinetic data. If the oral effects are real, they may be mediated by local intestinal gene expression changes, receptor-mediated luminal effects, or fragments produced by partial digestion, none of which have been characterized.
Vesugen occupies a distinctive position in the Khavinson bioregulator family because it has more human exposure data than any of its siblings. While Epithalon, Cortagen, and Vilon remain entirely in animal and cell culture territory for clinical evidence, Vesugen has small Russian observational studies in real patients with real vascular disease: 41 post-surgical lower limb ischemia cases, a series of atherosclerosis and hypertension patients using it as an adjunct to standard therapy, and vasculogenic erectile dysfunction patients with Doppler-measured outcomes. These are not randomized trials, they are not blinded, and they originate from one institution, but they represent a different level of human exposure than most compounds in this class.
The mechanistic case is also more developed than most Khavinson bioregulators. The MKI67 promoter docking, the endothelin-1 normalization in atherosclerosis-modeled endothelial cultures, and the SIRT1 upregulation are each individually meaningful findings that connect to well-validated biology of vascular aging and endothelial dysfunction. The 2021 Pharmaceuticals Alzheimer's mouse study represents the only Khavinson bioregulator study at this tier with meaningful international co-authorship and publication in a PubMed-indexed open-access journal with external peer review.
What Vesugen lacks is the same thing all Khavinson bioregulators lack: a single placebo-controlled randomized trial. The observational human data provide a directional signal strong enough to justify a properly designed Phase 2 trial, but that trial has not been conducted in a Western setting and none appears to be in progress based on available registries. Until controlled data exist, the clinical claims for Vesugen should be treated as hypothesis-generating, not practice-informing. The compound is among the most scientifically interesting in the bioregulator class and among the most plausible candidates for genuine cardiovascular clinical activity, but plausibility and interest are not efficacy.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use